Figure 6

Intensity of CD64 on high-density neutrophils can predict overall survival in multiple myeloma patients. In circulating neutrophils, identified as CD45⁺CD11b⁺CD15⁺CD14⁻ cells, obtained from peripheral blood of healthy, MGUS and MM patients we measured the mean of fluorescence intensity of surface expression of CD64 (A) and CD16 (B). Stars denote p-value (***p < 0.001, *p < 0.05) using t-test. Based on the reduction of monoclonal component in serum/urine patients and consequently response after 4 cycles of induction treatment, patients were distinguished in two groups: those who obtained at least a partial response (equivalent to reduction of at least 50% of monoclonal component from baseline) or not (identified as stable or progressive disease). Overall survival was defined as time from the date of initial diagnosis to the date of death for any reason or last follow-up in two groups of patients distinguished based on CD64 (C) or CD16 (D) MFI, using as threshold the mean value plus 2 standard deviation found in healthy subjects.